Kazia Therapeutics (Kazia Therapeutics) ROE % Adjusted to Book Value

: -35.51% (As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

Kazia Therapeutics's ROE % for the quarter that ended in Jun. 2023 was -116.13%. Kazia Therapeutics's PB Ratio for the quarter that ended in Jun. 2023 was 3.27. Kazia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was -35.51%.

Kazia Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Kazia Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-35.60

-26.68

-7.40

-18.53

-40.14

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-2.65	-13.13	-23.53	-137.59	-35.51

Competitive Comparison

For the Biotechnology subindustry, Kazia Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kazia Therapeutics ROE % Adjusted to Book Value Distribution

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's ROE % Adjusted to Book Value falls into.

Kazia Therapeutics ROE % Adjusted to Book Value Calculation

Kazia Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-131.25%	/	3.27
	=	-40.14%

Kazia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-116.13%	/	3.27
	=	-35.51%

Kazia Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204